Background: Clinical trial eligible patients with advanced non-small cell lung cancer (aNSCLC) and low programmed cell death ligand 1 (PD-L1) expression achieve greater benefit from immune checkpoint inhibitor (ICI) combination chemotherapy (ICI-Chemo) compared with Chemo alone. We examined whether patients ineligible for clinical trials may benefit from ICI-Chemo.
Methods: This multicenter retrospective cohort study enrolled patients with aNSCLC, including unresectable Stage III (IIIB/IIIC) and IV disease with a PD-L1 tumor proportion score of 1-49% treated with ICI-Chemo or Chemo as first-line therapy from 2018 to 2023 in Japan. Treatment outcome and safety of ICI-Chemo versus Chemo groups in trial-eligible and trial-ineligible patients was compared based on criteria from previous phase III clinical trials.
Results: Overall, 728 patients were analyzed: 333 trial-eligible and 395 ineligible patients. The median overall survival was 25.1 months in the ICI-Chemo group and 18.5 months in the Chemo group for eligible patients (HR 0.73, 95 %CI: 0.54-0.97) and was 18.2 months in the ICI-Chemo group and 14.9 months in the Chemo group for ineligible patients (HR 0.75, 95 %CI: 0.59-0.95). Median progression-free survival was longer with ICI-Chemo in both groups. For ineligible patients, performance status (PS) ≥ 2 and squamous cell carcinoma (SqCC) were clinical factors associated with worse survival prognosis, and survival outcomes with ICI-Chemo and Chemo were comparable. The ineligible group had no increase in severe adverse events compared to the eligible group.
Conclusions: This study suggests a possible clinical benefit of receiving ICI-Chemo for trial-ineligible patients with low PD-L1 expression, excluding those with PS ≥ 2 or SqCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lungcan.2025.108104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical Chart Review.
Clin Genitourin Cancer
February 2025
Department of Urology, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address:
Introduction: Treatment patterns for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC) are inconsistently reported. We retrospectively described demographic, clinical, and treatment characteristics for these patients and assessed their clinical outcomes.
Patients And Methods: Medical charts of patients with BCG-unresponsive high-risk NMIBC (carcinoma in situ [cohort A] or T1/high-grade Ta [cohort B]) who were ineligible for or declined RC documented between January 1, 2011, and December 31, 2018, at 15 academic centers were reviewed.
Results of rapid plasma direct oral anticoagulant levels greatly expand stroke thrombolysis eligibility: evidence from real-world implementation.
Intern Med J
March 2025
Department of Neurosciences, Eastern Health, Melbourne, Victoria, Australia.
Direct oral anticoagulants (DOACs) are used for stroke prevention in atrial fibrillation, but their presence can limit thrombolysis eligibility in acute stroke. This retrospective study examined whether rapid plasma DOAC testing expanded eligibility for thrombolysis. Among ischaemic stroke patients taking DOACs who were otherwise eligible for thrombolysis, 40% had low DOAC levels (<50 ng/mL).
View Article and Find Full Text PDFA real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
Blood Cancer J
March 2025
Department of Hematology-Oncology, Medical University of South Carolina, Charleston, SC, USA.
While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading to its withdrawal from commercial use. With an imminent approval as an effective combination therapy, as seen in recent randomized trials, we report real-world clinical outcomes with belantamab mafodotin in 81 RRMM patients. With a median of 5 (range 2-15) prior lines of therapy, 92, 45, and 15% of the patients were triple-class refractory, penta-class refractory, and BCMA-refractory.
View Article and Find Full Text PDFIdentifying the Unmet Healthcare Needs of Kidney Transplant Recipients Who Experience Graft Loss: Learning From Patients' Experience.
Transplantation
March 2025
MEDIC, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Background: Kidney transplant recipients with graft loss (KTR-GL) are an increasing group of patients whose care needs are largely unmet. The lack of patient perspectives is a key research gap. We conducted an in-depth exploration of the experiences of KTR-GL to identify their healthcare needs.
View Article and Find Full Text PDFThe challenge of treating hepatitis C virus infection in children with comorbidities.
Eur J Pediatr
March 2025
Pediatric Hepatology Unit, Department of Pediatrics, Cairo University, Cairo, Egypt.
Unlabelled: Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment and enabled the treatment of those who could not be treated using interferon. The aim of this work was to assess the efficacy and safety of oral DAAs in HCV-infected children with associated comorbidities. This analytical retrospective study included children with HCV mono-infection versus those with associated comorbidities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!